secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2023-03-03T23:59:59+00:00
Accession:  0001193125-23-060044
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics appoints Brendan Hannah as principal financial officer after Ted Monohon resigns
--------------------------------------------------------------------------------

- Ted Monohon resigns as Chief Accounting Officer and VP of Finance, effective March 16, 2023; no disagreement with company.
- Brendan Hannah, current Chief Business Officer, appointed as principal financial officer and principal accounting officer effective March 16, 2023.
- Hannah's compensation unchanged; no family relationships or reportable transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312523060044/0001193125-23-060044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312523060044/d146910d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-060044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer